Culture of Melanoma Cells in 3-Dimensional Architectures Results in Impaired Immunorecognition by Cytotoxic T Lymphocytes Specific for Melan-A/MART-1 Tumor-Associated Antigen

Objective:To assess the effects of the culture of melanoma cells in 3-dimensional (3D) architectures on their immunorecognition by cytotoxic T lymphocytes (CTLs) specific for tumor-associated antigens. Summary Background Data:Growth in 3D architectures has been shown to promote the resistance of cancers to treatment with drugs, cytokines, or irradiation, thereby potentially playing an important role in tumor expansion. We investigated the effects of 3D culture on the recognition of melanoma cells by antigen-specific HLA class I-restricted CTLs. Methods:Culture of HBL melanoma cells expressing Melan-A/Mart-1 tumor-associated antigen and HLA-A0201 on poly-2-hydroxyethyl methacrylate (polyHEMA)-coated plates resulted in the generation of aggregates of 400- to 500-μm diameters containing on average 30,000 cells and characterized by slower proliferation, as compared with monolayer (2-dimensional) cultures. HLA-A0201 restricted Melan-A/Mart-127–35-specific CTL clones were used to evaluate tumor cell immunorecognition measured as specific IFN-γ production. Comparative gene and protein expression in 2D and 3D cultures was studied by real-time PCR and flow cytometry, respectively. Overall differences in gene expression profiles between 2D and 3D cultures were evaluated by high-density oligonucleotide array hybridization. Results:HLA-A0201 restricted Melan-A/Mart-127–35 specific CTL clones produced high amounts of IFN-γ upon short-term (4–24 hours) coincubation with HBL cells cultured in 2D but not in 3D, thus suggesting altered antigen recognition. Indeed, Melan-A/Mart-1 expression, at both gene and protein levels, was significantly decreased in 3D as compared with 2D cultures. Concomitantly, a parallel decrease of HLA class I molecule expression was also observed. Differential gene profiling studies on HBL cells showed an increased expression of genes encoding molecules involved in intercellular adhesion, such as junctional adhesion molecule 2 and cadherin-like 1 (>20- and 8-fold up-regulated, respectively) in 3D as compared with 2D cultures. Conclusions:Taken together, our data suggest that mere growth of melanoma cells in 3D architectures, in the absence of immunoselective pressure, may result in defective recognition by tumor-associated antigen-specific CTL.

[1]  F. Marincola,et al.  Correspondence 1: Cancer vaccines: pessimism in check , 2004, Nature Network Boston.

[2]  B. Brors,et al.  Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters , 2004, The Journal of experimental medicine.

[3]  Pierre Validire,et al.  Impact of human bladder cancer cell architecture on autologous T‐lymphocyte activation , 2002, International journal of cancer.

[4]  B. Seliger,et al.  HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.

[5]  J. Folkman,et al.  Role of cell shape in growth control , 1978, Nature.

[6]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[7]  Ivan Martin,et al.  Three‐dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study , 2005, Journal of cellular physiology.

[8]  G. Parmiani,et al.  Vaccination of patients with solid tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[10]  A. Anichini,et al.  The paradox of T cell–mediated antitumor immunity in spite of poor clinical outcome in human melanoma , 2004, Cancer Immunology, Immunotherapy.

[11]  G Vallancien,et al.  Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns , 2002, British Journal of Cancer.

[12]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[13]  E. Padovan,et al.  Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. , 2003, Human gene therapy.

[14]  V. Cerundolo,et al.  An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.

[15]  S. Richon,et al.  A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. , 2003, Cancer research.

[16]  I. S. Dunn,et al.  A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter , 2001, The Journal of Immunology.

[17]  I. S. Dunn,et al.  Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. , 2003, Molecular cancer research : MCR.

[18]  P. Meltzer,et al.  Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. , 2002, Critical reviews in oncology/hematology.

[19]  R. Hamid,et al.  Comparison of alamar blue and MTT assays for high through-put screening. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[20]  E. Padovan,et al.  Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. , 2002, Human gene therapy.

[21]  F. Marincola,et al.  Natural T cell immunity against cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S. Pervaiz,et al.  Melanoma antigen recognition by tumour‐infiltrating T lymphocytes (TIL): effect of differential expression of Melan‐A/MART‐1 , 2000, Clinical and experimental immunology.

[23]  G. Bazzoni The JAM family of junctional adhesion molecules. , 2003, Current opinion in cell biology.

[24]  U. Certa,et al.  High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells , 2001, British Journal of Cancer.

[25]  F. Jotereau,et al.  Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.